France · Delayed Price · Currency is EUR Sanofi Company Description
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions.
It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for a natural killer cell engager program targeting B7-H3.
Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and and Insilico Medicine to use Pharma.AI, a medicine’s AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies.
Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV’574, which is used for treatment of ulcerative colitis and Crohn’s disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab.
The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
| Country | France |
| Founded | 1994 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 82,878 |
| CEO | Olivier Charmeil |
Contact Details
Address: 46, avenue de la Grande Armée Paris, 75017 France | |
| Phone | 33 1 53 77 40 00 |
| Website | sanofi.com |
Stock Details
| Ticker Symbol | SAN |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0000120578 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Hudson | Chief Executive Officer and Director |
| François-Xavier Roger | Executive Vice President and Chief Financial Officer |
| Madeleine Roach | Executive Vice President and Head of Business Operations |
| Thomas Kudsk Larsen | Head of Investor Relations and General Medicines |
| Roy Papatheodorou | Executive Vice President and General Counsel |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing |
| Natalie Bickford | Executive Vice President and Chief People Officer |
| Olivier Charmeil | Executive Vice President of General Medicines |
| Fabrizio Gaudi | Head of Austrian, German and Swiss Operations |
| Erik Wallström | Head of Therapeutic Area - Neurology Development |